Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, California, USA.
J Vet Intern Med. 2024 Sep-Oct;38(5):2548-2555. doi: 10.1111/jvim.17167. Epub 2024 Sep 16.
Recurrent bacterial cystitis, often referred to as recurrent urinary tract infection (UTI), can be difficult to manage and alternative treatments are needed.
HYPOTHESIS/OBJECTIVE: Intravesicular administration of asymptomatic bacteriuria (ASB) E. coli 212 will not be inferior to antimicrobial treatment for the management of recurrent UTI in dogs.
Thirty-four dogs with >1 UTI in the 12 months before presentation.
All dogs were deemed normal otherwise based on absence of abnormalities on physical examination, CBC, serum biochemical panel, and abdominal ultrasonography. Dogs were randomized to 1 of 2 treatment groups: Group 1 antimicrobials for 7 days or group 2 intravesicular administration of ASB E. coli 212. Owners were provided a voiding questionnaire regarding their dogs' clinical signs, which was completed daily for 14 days to assess clinical cure. Dogs were examined on days 7 and 14 to assess clinical cure, and urine specimens were submitted for urinalysis and bacterial culture.
Clinical cure rates for ASB E. coli 212-treated dogs were not inferior to 7 days of antimicrobial treatment with a 12% margin of difference to determine non-inferiority. No significant difference was found between the treatment groups on days 7 and 14 in the proportion of dogs achieving ≥50% or ≥75% reduction in their clinical score compared with baseline.
These data suggest that intravesicular administration of ASB E. coli 212 is not inferior to antimicrobials for the treatment of recurrent UTI in dogs. This biotherapeutic agent could help alleviate the need for antimicrobials for some dogs with recurrent UTI, improving antimicrobial stewardship.
复发性细菌性膀胱炎，通常称为复发性尿路感染（UTI），可能难以治疗，需要替代治疗。
假说/目的：无症状菌尿（ASB）E. coli 212 的膀胱内给药不会劣于抗菌治疗用于管理犬复发性 UTI。
34 只在就诊前 12 个月内有 >1 次 UTI 的狗。
所有狗都被认为是正常的，因为体格检查、CBC、血清生化分析和腹部超声检查均无异常。狗被随机分为 2 个治疗组之一：组 1 用抗菌药物治疗 7 天或组 2 用 ASB E. coli 212 进行膀胱内给药。主人提供了关于他们狗的临床症状的排尿问卷，每天完成一次，持续 14 天，以评估临床治愈情况。在第 7 天和第 14 天检查狗以评估临床治愈情况，并提交尿液样本进行尿液分析和细菌培养。
ASB E. coli 212 治疗组的临床治愈率不劣于抗菌治疗 7 天，差异 12%确定非劣效性。与基线相比，在第 7 天和第 14 天，两组之间达到临床评分≥50%或≥75%降低的狗的比例没有显著差异。
这些数据表明，ASB E. coli 212 的膀胱内给药与抗菌治疗犬复发性 UTI 不劣效。这种生物治疗剂可以帮助减轻一些复发性 UTI 狗对抗生素的需求，改善抗生素管理。
